Regenxbio Inc (RGNX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access RGNX Annual Balance Sheets →
Reviewing balance sheet data across recent quarters allows users to assess how Regenxbio Inc manages assets, liabilities, and equity through different cycles.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent105.50
Marketable Securities, Current SH69.03
Cash & Short-term Investments174.00
Accounts receivable107.19
Other Current Assets0.00
Prepaid Expense, Current AS11.90
Total Current Assets236.16
Equipment/Property/Plant Net192.38
Long-term investments0.44
Other Assets, Noncurrent0.00
Total Assets386.62
Liabilities
Accounts Payable, Current AC15.55
Accrued Liabilities, Current AC12.96
Other Liabilities, Current54.12
Total Current Liabilities82.62
Total Long-term Debt0.00
Other liabilities, Noncurrent232.23
Accrued Expenses And Other Current Liabilities21.89
Contract With Customer Liability Noncurrent22.78
Total Liabilities314.85
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,266.00
Retained Earnings / Accumulated Deficit-1,193.37
Accumulated Other Comprehensive Income-0.88
Other Equity-0.88
Common Stockholder's Equity71.77
Total Stockholder's Equity71.77
Liabilities & Stockholder's Equity386.62
4 historic quarters locked

Sign in to unlock the full Regenxbio Inc balance sheet history.

About Regenxbio Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-336725

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.